Selected research
Market Analysis & Forecast
Global Kidney Cancer Targeted Therapy Market Analysis and Forecast 2026-2032
Market perspective
The global Kidney Cancer Targeted Therapy market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The North America market for Kidney Cancer Targeted Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Europe market for Kidney Cancer Targeted Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Read the full market overview
Asia-Pacific market for Kidney Cancer Targeted Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The China market for Kidney Cancer Targeted Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The major global companies of Kidney Cancer Targeted Therapy include Aveo Pharmaceuticals, Exelixis, Wyeth, Amgen, Bayer, Pfizer, Roche, Merck and Novartis, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for Kidney Cancer Targeted Therapy, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.
This report researches the key producers of Kidney Cancer Targeted Therapy, also provides the revenue of main regions and countries. Of the upcoming market potential for Kidney Cancer Targeted Therapy, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Kidney Cancer Targeted Therapy revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Kidney Cancer Targeted Therapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Kidney Cancer Targeted Therapy revenue, projected growth trends, production technology, application and end-user industry.
Kidney Cancer Targeted Therapy Segment by Company
Aveo Pharmaceuticals
Exelixis
Wyeth
Amgen
Bayer
Pfizer
Roche
Merck
Novartis
Eisai
Kidney Cancer Targeted Therapy Segment by Type
Tyrosine Kinase Inhibitors
Anti-VEGF Monoclonal Antibody
mTOR Inhibitors
EGFR Inhibitors
Kidney Cancer Targeted Therapy Segment by Application
Renal Cell Cancer
Renal Pelvis Cancer
Others
Kidney Cancer Targeted Therapy Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Kidney Cancer Targeted Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Kidney Cancer Targeted Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Kidney Cancer Targeted Therapy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Kidney Cancer Targeted Therapy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Kidney Cancer Targeted Therapy company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Kidney Cancer Targeted Therapy revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Tyrosine Kinase Inhibitors
- Anti-VEGF Monoclonal Antibody
- mTOR Inhibitors
- EGFR Inhibitors
Applications
- Renal Cell Cancer
- Renal Pelvis Cancer
- Others
Companies covered
- Aveo Pharmaceuticals
- Exelixis
- Wyeth
- Amgen
- Bayer
- Pfizer
- Roche
- Merck
- Novartis
- Eisai
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Kidney Cancer Targeted Therapy Market by Type
- 1.2.1 Global Kidney Cancer Targeted Therapy Market Size by Type, 2021 VS 2025 VS 2032
- 1.2.2 Tyrosine Kinase Inhibitors
- 1.2.3 Anti-VEGF Monoclonal Antibody
- 1.2.4 mTOR Inhibitors
- 1.2.5 EGFR Inhibitors
- 1.3 Kidney Cancer Targeted Therapy Market by Application
- 1.3.1 Global Kidney Cancer Targeted Therapy Market Size by Application, 2021 VS 2025 VS 2032
- 1.3.2 Renal Cell Cancer
- 1.3.3 Renal Pelvis Cancer
- 1.3.4 Others
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Kidney Cancer Targeted Therapy Market Dynamics
- 2.1 Kidney Cancer Targeted Therapy Industry Trends
- 2.2 Kidney Cancer Targeted Therapy Industry Drivers
- 2.3 Kidney Cancer Targeted Therapy Industry Opportunities and Challenges
- 2.4 Kidney Cancer Targeted Therapy Industry Restraints
3 Global Growth Perspective
- 3.1 Global Kidney Cancer Targeted Therapy Market Perspective (2021-2032)
- 3.2 Global Kidney Cancer Targeted Therapy Growth Trends by Region
- 3.2.1 Global Kidney Cancer Targeted Therapy Market Size by Region: 2021 VS 2025 VS 2032
- 3.2.2 Global Kidney Cancer Targeted Therapy Market Size by Region (2021-2026)
- 3.2.3 Global Kidney Cancer Targeted Therapy Market Size by Region (2027-2032)
4 Competitive Landscape by Players
- 4.1 Global Kidney Cancer Targeted Therapy Revenue by Players
- 4.1.1 Global Kidney Cancer Targeted Therapy Revenue by Players (2021-2026)
- 4.1.2 Global Kidney Cancer Targeted Therapy Revenue Market Share by Players (2021-2026)
- 4.1.3 Global Kidney Cancer Targeted Therapy Players Revenue Share Top 10 and Top 5 in 2025
- 4.2 Global Kidney Cancer Targeted Therapy Key Players Ranking, 2024 VS 2025 VS 2026
- 4.3 Global Kidney Cancer Targeted Therapy Key Players Headquarters & Area Served
- 4.4 Global Kidney Cancer Targeted Therapy Players, Product Type & Application
- 4.5 Global Kidney Cancer Targeted Therapy Players Establishment Date
- 4.6 Market Competitive Analysis
- 4.6.1 Global Kidney Cancer Targeted Therapy Market CR5 and HHI
- 4.6.3 2025 Kidney Cancer Targeted Therapy Tier 1, Tier 2, and Tier 3
5 Kidney Cancer Targeted Therapy Market Size by Type
- 5.1 Global Kidney Cancer Targeted Therapy Revenue by Type (2021 VS 2025 VS 2032)
- 5.2 Global Kidney Cancer Targeted Therapy Revenue by Type (2021-2032)
- 5.3 Global Kidney Cancer Targeted Therapy Revenue Market Share by Type (2021-2032)
6 Kidney Cancer Targeted Therapy Market Size by Application
- 6.1 Global Kidney Cancer Targeted Therapy Revenue by Application (2021 VS 2025 VS 2032)
- 6.2 Global Kidney Cancer Targeted Therapy Revenue by Application (2021-2032)
- 6.3 Global Kidney Cancer Targeted Therapy Revenue Market Share by Application (2021-2032)
7 Company Profiles
- 7.1 Aveo Pharmaceuticals
- 7.1.1 Aveo Pharmaceuticals Company Information
- 7.1.2 Aveo Pharmaceuticals Business Overview
- 7.1.3 Aveo Pharmaceuticals Kidney Cancer Targeted Therapy Revenue and Gross Margin (2021-2026)
- 7.1.4 Aveo Pharmaceuticals Kidney Cancer Targeted Therapy Product Portfolio
- 7.1.5 Aveo Pharmaceuticals Recent Developments
- 7.2 Exelixis
- 7.2.1 Exelixis Company Information
- 7.2.2 Exelixis Business Overview
- 7.2.3 Exelixis Kidney Cancer Targeted Therapy Revenue and Gross Margin (2021-2026)
- 7.2.4 Exelixis Kidney Cancer Targeted Therapy Product Portfolio
- 7.2.5 Exelixis Recent Developments
- 7.3 Wyeth
- 7.3.1 Wyeth Company Information
- 7.3.2 Wyeth Business Overview
- 7.3.3 Wyeth Kidney Cancer Targeted Therapy Revenue and Gross Margin (2021-2026)
- 7.3.4 Wyeth Kidney Cancer Targeted Therapy Product Portfolio
- 7.3.5 Wyeth Recent Developments
- 7.4 Amgen
- 7.4.1 Amgen Company Information
- 7.4.2 Amgen Business Overview
- 7.4.3 Amgen Kidney Cancer Targeted Therapy Revenue and Gross Margin (2021-2026)
- 7.4.4 Amgen Kidney Cancer Targeted Therapy Product Portfolio
- 7.4.5 Amgen Recent Developments
- 7.5 Bayer
- 7.5.1 Bayer Company Information
- 7.5.2 Bayer Business Overview
- 7.5.3 Bayer Kidney Cancer Targeted Therapy Revenue and Gross Margin (2021-2026)
- 7.5.4 Bayer Kidney Cancer Targeted Therapy Product Portfolio
- 7.5.5 Bayer Recent Developments
- 7.6 Pfizer
- 7.6.1 Pfizer Company Information
- 7.6.2 Pfizer Business Overview
- 7.6.3 Pfizer Kidney Cancer Targeted Therapy Revenue and Gross Margin (2021-2026)
- 7.6.4 Pfizer Kidney Cancer Targeted Therapy Product Portfolio
- 7.6.5 Pfizer Recent Developments
- 7.7 Roche
- 7.7.1 Roche Company Information
- 7.7.2 Roche Business Overview
- 7.7.3 Roche Kidney Cancer Targeted Therapy Revenue and Gross Margin (2021-2026)
- 7.7.4 Roche Kidney Cancer Targeted Therapy Product Portfolio
- 7.7.5 Roche Recent Developments
- 7.8 Merck
- 7.8.1 Merck Company Information
- 7.8.2 Merck Business Overview
- 7.8.3 Merck Kidney Cancer Targeted Therapy Revenue and Gross Margin (2021-2026)
- 7.8.4 Merck Kidney Cancer Targeted Therapy Product Portfolio
- 7.8.5 Merck Recent Developments
- 7.9 Novartis
- 7.9.1 Novartis Company Information
- 7.9.2 Novartis Business Overview
- 7.9.3 Novartis Kidney Cancer Targeted Therapy Revenue and Gross Margin (2021-2026)
- 7.9.4 Novartis Kidney Cancer Targeted Therapy Product Portfolio
- 7.9.5 Novartis Recent Developments
- 7.10 Eisai
- 7.10.1 Eisai Company Information
- 7.10.2 Eisai Business Overview
- 7.10.3 Eisai Kidney Cancer Targeted Therapy Revenue and Gross Margin (2021-2026)
- 7.10.4 Eisai Kidney Cancer Targeted Therapy Product Portfolio
- 7.10.5 Eisai Recent Developments
8 North America
- 8.1 North America Kidney Cancer Targeted Therapy Revenue (2021-2032)
- 8.2 North America Kidney Cancer Targeted Therapy Revenue by Type (2021-2032)
- 8.2.1 North America Kidney Cancer Targeted Therapy Revenue by Type (2021-2026)
- 8.2.2 North America Kidney Cancer Targeted Therapy Revenue by Type (2027-2032)
- 8.3 North America Kidney Cancer Targeted Therapy Revenue Share by Type (2021-2032)
- 8.4 North America Kidney Cancer Targeted Therapy Revenue by Application (2021-2032)
- 8.4.1 North America Kidney Cancer Targeted Therapy Revenue by Application (2021-2026)
- 8.4.2 North America Kidney Cancer Targeted Therapy Revenue by Application (2027-2032)
- 8.5 North America Kidney Cancer Targeted Therapy Revenue Share by Application (2021-2032)
- 8.6 North America Kidney Cancer Targeted Therapy Revenue by Country
- 8.6.1 North America Kidney Cancer Targeted Therapy Revenue by Country (2021 VS 2025 VS 2032)
- 8.6.2 North America Kidney Cancer Targeted Therapy Revenue by Country (2021-2026)
- 8.6.3 North America Kidney Cancer Targeted Therapy Revenue by Country (2027-2032)
- 8.6.4 United States
- 8.6.5 Canada
9 Europe
- 9.1 Europe Kidney Cancer Targeted Therapy Revenue (2021-2032)
- 9.2 Europe Kidney Cancer Targeted Therapy Revenue by Type (2021-2032)
- 9.2.1 Europe Kidney Cancer Targeted Therapy Revenue by Type (2021-2026)
- 9.2.2 Europe Kidney Cancer Targeted Therapy Revenue by Type (2027-2032)
- 9.3 Europe Kidney Cancer Targeted Therapy Revenue Share by Type (2021-2032)
- 9.4 Europe Kidney Cancer Targeted Therapy Revenue by Application (2021-2032)
- 9.4.1 Europe Kidney Cancer Targeted Therapy Revenue by Application (2021-2026)
- 9.4.2 Europe Kidney Cancer Targeted Therapy Revenue by Application (2027-2032)
- 9.5 Europe Kidney Cancer Targeted Therapy Revenue Share by Application (2021-2032)
- 9.6 Europe Kidney Cancer Targeted Therapy Revenue by Country
- 9.6.1 Europe Kidney Cancer Targeted Therapy Revenue by Country (2021 VS 2025 VS 2032)
- 9.6.2 Europe Kidney Cancer Targeted Therapy Revenue by Country (2021-2026)
- 9.6.3 Europe Kidney Cancer Targeted Therapy Revenue by Country (2027-2032)
- 9.6.4 Germany
- 9.6.5 France
- 9.6.6 U.K.
- 9.6.7 Italy
- 9.6.8 Netherlands
10 China
- 10.1 China Kidney Cancer Targeted Therapy Revenue (2021-2032)
- 10.2 China Kidney Cancer Targeted Therapy Revenue by Type (2021-2032)
- 10.2.1 China Kidney Cancer Targeted Therapy Revenue by Type (2021-2026)
- 10.2.2 China Kidney Cancer Targeted Therapy Revenue by Type (2027-2032)
- 10.3 China Kidney Cancer Targeted Therapy Revenue Share by Type (2021-2032)
- 10.4 China Kidney Cancer Targeted Therapy Revenue by Application (2021-2032)
- 10.4.1 China Kidney Cancer Targeted Therapy Revenue by Application (2021-2026)
- 10.4.2 China Kidney Cancer Targeted Therapy Revenue by Application (2027-2032)
- 10.5 China Kidney Cancer Targeted Therapy Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
- 11.1 Asia Kidney Cancer Targeted Therapy Revenue (2021-2032)
- 11.2 Asia Kidney Cancer Targeted Therapy Revenue by Type (2021-2032)
- 11.2.1 Asia Kidney Cancer Targeted Therapy Revenue by Type (2021-2026)
- 11.2.2 Asia Kidney Cancer Targeted Therapy Revenue by Type (2027-2032)
- 11.3 Asia Kidney Cancer Targeted Therapy Revenue Share by Type (2021-2032)
- 11.4 Asia Kidney Cancer Targeted Therapy Revenue by Application (2021-2032)
- 11.4.1 Asia Kidney Cancer Targeted Therapy Revenue by Application (2021-2026)
- 11.4.2 Asia Kidney Cancer Targeted Therapy Revenue by Application (2027-2032)
- 11.5 Asia Kidney Cancer Targeted Therapy Revenue Share by Application (2021-2032)
- 11.6 Asia Kidney Cancer Targeted Therapy Revenue by Country
- 11.6.1 Asia Kidney Cancer Targeted Therapy Revenue by Country (2021 VS 2025 VS 2032)
- 11.6.2 Asia Kidney Cancer Targeted Therapy Revenue by Country (2021-2026)
- 11.6.3 Asia Kidney Cancer Targeted Therapy Revenue by Country (2027-2032)
- 11.6.4 Japan
- 11.6.5 South Korea
- 11.6.6 India
- 11.6.7 Australia
- 11.6.8 Taiwan
- 11.6.9 Southeast Asia
12 South America, Middle East and Africa
- 12.1 SAMEA Kidney Cancer Targeted Therapy Revenue (2021-2032)
- 12.2 SAMEA Kidney Cancer Targeted Therapy Revenue by Type (2021-2032)
- 12.2.1 SAMEA Kidney Cancer Targeted Therapy Revenue by Type (2021-2026)
- 12.2.2 SAMEA Kidney Cancer Targeted Therapy Revenue by Type (2027-2032)
- 12.3 SAMEA Kidney Cancer Targeted Therapy Revenue Share by Type (2021-2032)
- 12.4 SAMEA Kidney Cancer Targeted Therapy Revenue by Application (2021-2032)
- 12.4.1 SAMEA Kidney Cancer Targeted Therapy Revenue by Application (2021-2026)
- 12.4.2 SAMEA Kidney Cancer Targeted Therapy Revenue by Application (2027-2032)
- 12.5 SAMEA Kidney Cancer Targeted Therapy Revenue Share by Application (2021-2032)
- 12.6 SAMEA Kidney Cancer Targeted Therapy Revenue by Country
- 12.6.1 SAMEA Kidney Cancer Targeted Therapy Revenue by Country (2021 VS 2025 VS 2032)
- 12.6.2 SAMEA Kidney Cancer Targeted Therapy Revenue by Country (2021-2026)
- 12.6.3 SAMEA Kidney Cancer Targeted Therapy Revenue by Country (2027-2032)
- 12.6.4 Brazil
- 12.6.5 Argentina
- 12.6.6 Chile
- 12.6.7 Colombia
- 12.6.8 Peru
- 12.6.9 Saudi Arabia
- 12.6.10 Israel
- 12.6.11 UAE
- 12.6.12 Turkey
- 12.6.13 Iran
- 12.6.14 Egypt
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst